Form 4: Jupiter Neurosciences CSO Receives Stock Option Grant

Chief Scientific Officer Marshall A. Hayward was granted 259,231 stock options as a discretionary bonus for 2025 services.

Summary

• Marshall A. Hayward, Chief Scientific Officer of Jupiter Neurosciences, Inc., received a grant of 259,231 stock options.
• The options were issued under the company's 2025 Equity Incentive Plan.
• The grant serves as a discretionary bonus for services rendered during the 2025 fiscal year.
• The options have an exercise price of $0.2783 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in the company's fundamental outlook.

Positives

• Aligns the interests of the Chief Scientific Officer with long-term shareholder value through equity-based compensation.
• Retention mechanism implemented via a three-year vesting schedule.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Continued employment is required for the vesting of these options, creating a dependency on key personnel retention.
• The value of the options is subject to market volatility and the future performance of the company's common stock.

Future Outlook

The options vest in equal quarterly installments over three years starting September 2, 2026, contingent upon continued employment.

Management Comments

• The grant is explicitly identified as a discretionary bonus for services rendered during fiscal 2025.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice for biotechnology firms to preserve cash while incentivizing executive leadership to achieve clinical and commercial milestones.

Comparison to Industry Standards

• The use of a three-year vesting schedule is consistent with standard corporate governance practices for executive equity awards in the small-cap biotech sector.
• Discretionary bonuses in the form of stock options are common among early-stage companies to manage liquidity.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options to commence on September 2, 2026.

Key Dates

Keywords

Jupiter Neurosciences, JUNS, Form 4, Stock Options, Insider Compensation, Equity Incentive Plan